Previous 10 | Next 10 |
- Alpine to hold Investor Event on Friday, June 4 at 7:00pm ET - - Program abstracts are now live on the ASCO website - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer a...
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced an oral presentation of preclinical data from the company’s ALPN-303 program at ...
Alpine Immune Sciences (ALPN): Q1 GAAP EPS of -$0.45 misses by $0.09.Revenue of $3.2M (+193.6% Y/Y) misses by $4.55M.Press Release For further details see: Alpine Immune Sciences EPS misses by $0.09, misses on revenue
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the first quarter ended March 31,...
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced an upcoming presentation on NEON-1, the company’s Phase 1 clinical trial of ALPN...
The strategic agreement with AbbVie for the development of ALPN-101 is the most valuable asset of the company. The recent share price decline can be attributed to several factors, including the expected announcement of ALPN-101 Phase 2 trail initiation and the associated AbbVie agreem...
– NEON-1, clinical trial with ALPN-202 monotherapy, proceeds through dose escalation – – New discovery efforts yield novel preclinical fusion proteins that enable tumor antigen-dependent CD28 costimulation – Alpine Immune Sciences, Inc. (NAS...
Image source: The Motley Fool. Alpine Immune Sciences, Inc. (NASDAQ: ALPN) Q4 2020 Earnings Call Mar 18, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Alpine Immune Sciences, Inc. (ALPN) Q4 2020 Earnings Call Tran...
Alpine Immune Sciences, Inc. (ALPN) Q4 2020 Earnings Conference Call March 18, 2021 4:30 PM ET Company Participants Alex Sharif - Director, Investor Relations and Corporate Development Mitchell Gold - Executive Chairman and Chief Executive Officer Stanford Peng - President and Head of Researc...
Gainers: [[AAME]] +31.5%. [[MRKR]] +28.3%. [[KNSA]] +13.8%. [[WKEY]] +11.8%. [[SRPT]] +7.6%.Losers: [[PROG]] -6%. [[UPST]] -5.8%. [[ALPN]] -5.8%. [[SYBX]] -4.7%. [[ROAD]] -4.4%. For further details see: SRPT, UPST, MRKR and ALPN among after-hours movers
News, Short Squeeze, Breakout and More Instantly...
Alpine Immune Sciences Inc. Company Name:
ALPN Stock Symbol:
NASDAQ Market:
Alpine Immune Sciences Inc. Website:
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades...
2024-05-19 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceutic...